Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
CTOS 2023 – IDRx looks to outdo Deciphera
A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.
